NCT06868381尚未招募2 期
A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Proportion of patients with resolution of cardiac FDG uptake on PET-CT
研究概览
简要总结
The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:
- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT?
Participants will:
- Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks
- Visit the clinic every two to four weeks for checkups and tests
- Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of cardiac sarcoidosis based on one of the following pathways:
- •Histological Diagnosis
- •Myocardial or extracardiac biopsy demonstrating non-caseating granuloma with no alternative cause identified AND
- •Abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND
- •Exclusion of other causes for cardiac manifestations
- •Clinical Diagnosis
- •One or more of the following is present:
- •Steroid +/- immunosuppressant responsive cardiomyopathy or heart block
- •Unexplained reduced LVEF (< 40%) and/or segmental wall motion abnormalities not related to coronary artery disease or another defined cause
- •Unexplained sustained (spontaneous or induced) VT
- •Mobitz type II 2nd degree heart block or 3rd degree heart block
- •CT chest and/or FDG PET-CT showing features consistent with pulmonary sarcoidosis and/or hilar lymphadenopathy AND
- •Abnormal FDG uptake on cardiac PET-CT conducted within 6 weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND
- •Exclusion of other causes for cardiac manifestations
- •Active cardiac sarcoidosis based on abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis
- •No current treatment with immunosuppressive medications other than a steroid-sparing medication (including methotrexate, leflunomide, azathioprine, or mycophenolate mofetil), and/or prednisone (or equivalent) at a dose of ≤ 20mg daily at Baseline
排除标准
- •Receipt of a non-biologic DMARD or immunosuppressive agent other than methotrexate, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, or glucocorticoids within 28 days prior to screening
- •Receipt of a bDMARD or tsDMARD, including non-depleting B-cell-directed therapy (eg, belimumab), T cell costimulatory blockade (eg, abatacept), TNF-alpha inhibition (eg, infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), interleukin-6 inhibition (eg, tocilizumab, sarilumab), interleukin-1 inhibition (eg, anakinra), JAK inhibition (eg, tofacitinib, upadacitinib, baricitinib), or other biologic immunomodulatory agent within 28 days prior to screening
- •Receipt of any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab) in the 6 months prior to screening; receipt of such a B cell-depleting agent in the period 6-12 months prior to screening is exclusionary unless B cell counts have returned to ≥ LLN
- •History of venous thromboembolism (VTE) or an increased risk for VTE
- •Current smoking
- •Estimated glomerular filtration rate < 30 mL/min/1.73 m2 by Modification of Diet in Renal Disease Study (MDRD) equation
- •Blood tests at screening that meet any of the following criteria:
- •Hemoglobin < 7.5 g/dL
- •Neutrophils < 1000/mm3
- •Absolute lymphocyte count < 500/mm3
- •Platelets < 100 x 109/L
- •Subjects with the following abnormal liver function tests:
- •Aspartate aminotransferase (AST) > 2x ULN
- •Alanine aminotransferase (ALT) > 2x ULN
- •Total bilirubin (TBL) > 2x ULN unless AST, ALT, and hemoglobin are within central laboratory normal range and the patient has a known history of Gilbert syndrome
- •Active, clinically significant infection at the time of Screening
- •Active malignancy or history of malignancy that was active within the last 5 years, except as follows:
- •In situ carcinoma of the cervix following apparently curative therapy > 12 months prior to screening,
- •Cutaneous basal cell or squamous cell carcinoma following apparently curative therapy, or
- •Prostate cancer treated with radical prostatectomy or radiation therapy with curative intent > 3 years prior to screening and without known recurrence or current treatment
研究组 & 干预措施
baricitinib + steroid-sparing drug +/- glucocorticoid taper
Experimental
- Participants will be treated with baricitinib 4 mg daily for up to 16 weeks in combination with a background steroid sparing medication
- Participants who are on steroids at the time of enrollment will continue the steroid at a dose of prednisone (or equivalent) ≤ 20mg PO daily at Baseline and complete an 8 week taper of their steroid medication per a standardized protocol
干预措施: Baricitinib (LY3009104) 4 mg (Drug)
结局指标
主要结局
Proportion of patients with resolution of cardiac FDG uptake on PET-CT
时间窗: From baseline to end of treatment at 16 weeks
Resolution of FDG uptake will be determined by the consensus of two blinded nuclear medicine radiologists, in accordance with current SNMMI and ASNC guidelines
次要结局
- Percent change in FDG avidity (SUVmax) in the cardiac lesion with greatest FDG avidity on PET-CT(From baseline to 8 weeks and end of treatment at 16 weeks)
- Percent change in total cardiac metabolic activity on FDG PET-CT(From baseline to 8 weeks and end of treatment at 16 weeks)
- Proportion of patients with resolution of extracardiac FDG uptake on PET-CT(From baseline to 8 weeks and end of treatment at 16 weeks)
- Percent change in FDG avidity (SUVmax) in up to six extracardiac lesions on PET-CT(From baseline to 8 weeks and end of treatment at 16 weeks)
- Percent change in total extracardiac metabolic activity on FDG PET-CT(From baseline to 8 weeks and end of treatment at 16 weeks)
- Proportion of patients with resolution of cardiac FDG uptake on PET-CT(From baseline to 8 weeks and end of follow-up at 28 weeks)
- Change in sarcoidosis disease activity assessment(From baseline to 8 weeks and end of treatment at 16 weeks)
- Change in fatigue assessment(From baseline to 8 weeks and end of treatment at 16 weeks)
- Change from Baseline in Physician Disease Activity Visual Analogue Scale (VAS)(From baseline to 8 weeks and end of treatment at 16 weeks)
- Change from Baseline in Patient Disease Activity Visual Analogue Scale (VAS)(From baseline to 8 weeks and end of treatment at 16 weeks)
- Changes in ACE laboratory assessment(From baseline to 8 weeks and end of treatment at 16 weeks)
- Changes in high-sensitivity troponin I laboratory assessment(From baseline to 8 weeks and end of treatment at 16 weeks)
- Changes in NT-proBNP laboratory assessment(From baseline to 8 weeks and end of treatment at 16 weeks)
- Changes in total IgG laboratory assessment(From baseline to 8 weeks and end of treatment at 16 weeks)
- Changes in ESR laboratory assessment(From baseline to 8 weeks and end of treatment at 16 weeks)
- Changes in CRP laboratory assessment(From baseline to 8 weeks and end of treatment at 16 weeks)
- Number of participants with safety endpoints of interest(From screening to end of follow-up at 28 weeks)
研究者
Matthew C. Baker
Assistant Professor of Medicine
Stanford University
研究点 (1)
Loading locations...
相似试验
终止
2 期
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19Symptomatic COVID-19 Infection Laboratory-ConfirmedNCT04373044University of Southern California6
招募中
4 期
Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical TrialRheumatoid ArthritisNCT05827497Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh132
招募中
3 期
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataAreata AlopeciaHypotrichosisHair DiseasesSkin DiseasesPathological Conditions, AnatomicalAlopeciaNCT05723198Eli Lilly and Company595
已完成
3 期
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)Systemic Lupus ErythematosusNCT03616964Eli Lilly and Company778
终止
3 期
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT03616912Eli Lilly and Company830